A Grand Beginning of Nanjing Yyonda Pharmaceutical Co., Ltd.
author: Original
2025-02-22
Nanjing Yyonda Pharmaceutical Co., Ltd is committed to the field of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), adhering to the mission of "Empower the Innovation, Enhance the Quality." We provide high-quality products and services to global customers.
Our team members have an average of over 10 years of rich industry experience and have been deeply involved in multiple global innovative drug R&D projects. We have accumulated profound technical expertise in key areas such as organic synthesis, drug analysis, and domestic and international registration and filing.
Our business focuses on the full-cycle operation of pharmaceutical intermediates and APIs, deeply integrating R&D, production, and sales to create a complete and efficient industrial chain. In terms of R&D services, we offer:
-
Custom synthesis of new drug molecules, impurity standards ;
-
Custom production of pharmaceutical intermediates and APIs to meet diverse raw material needs of customers;
-
Bulk industry chemicals such fluorochemical, fragrances, etc.
-
Domestic and international registration consultation and submission services
We have established a strict quality management system in line with international standards to ensure product quality. Currently, the company has obtained the ISO 9001 Quality Management System certification.
With outstanding products and services, we have long-term cooperation with globally renowned pharmaceutical companies, and our products are widely sold in markets such as Europe, America, and Asia. Looking to the future, we will continue to innovate and increase R&D investment to work with partners and drive progress in the global pharmaceutical industry.

Darolutamide Improved Survival in Phase 3 Trials for Patients With Metastatic Hormone-Sensitive Prostate Cancer
Related Article

Key Takeaways
1. Darolutamide combined with SOC therapies significantly improves progression-free and overall survival in mHSPC patients, as shown in ARANOTE and ARASENS trials.
2. The ARANOTE trial demonstrated darolutamide's superior efficacy in both high and low disease volume subgroups, reducing radiological progression or death risk.
1. Darolutamide combined with SOC therapies significantly improves progression-free and overall survival in mHSPC patients, as shown in ARANOTE and ARASENS trials.
2. The ARANOTE trial demonstrated darolutamide's superior efficacy in both high and low disease volume subgroups, reducing radiological progression or death risk.
Darolutamide Improved Survival in Phase 3 Trials for Patients With Metastatic Hormone-Sensitive Prostate Cancer